Key result
Novel LC-MS/MS assay enables rapid simultaneous quantification of pioglitazone and candesartan in human plasma.
Why the study?
A validated, rapid, and simultaneous quantification method for pioglitazone and candesartan in human plasma was needed for pharmacokinetic studies.
A rapid and validated LC-MS/MS method was developed for the simultaneous quantification of pioglitazone and candesartan in human plasma, suitable for high-throughput pharmacokinetic studies.
Enables high-throughput PK studies of these agents; leaves open clinical translation pending further validation.
A simple and rapid liquid chromatography-tandem mass spectrometric (LC-MS/MS) assay method has been developed and fully validated for simultaneous quantification of pioglitazone and candesartan in human plasma. Irbesartan was used as an internal standard. The analytes were extracted from human plasma samples by solid-phase extraction technique using a Strata-X 33 μm polymeric sorbent. The reconstituted samples were chromatographed on a C18 column by using a 80:20 (v/v) mixture of acetonitrile and 0.1% formic acid as the mobile phase at a flow rate of 0.8 mL/min. The calibration curves obtained were linear (r≥0.99) over the concentration range of 15–3000 ng/mL for pioglitazone and 5–608 ng/mL for candesartan. The results of the intra- and inter-day precision and accuracy studies were well within the acceptable limits. A run time of 2.7 min for each sample made it possible to analyze more than 300 plasma samples per day. The proposed method was found to be applicable to clinical studies.
No takes yet. Share an insight, caveat, or question.
Karra et al. (2012) studied this question. LC-MS/MS assay for pioglitazone and candesartan was evaluated on Simultaneous quantification of pioglitazone and candesartan in human plasma. A simple and rapid LC-MS/MS assay method was successfully developed and validated for the simultaneous quantification of pioglitazone and candesartan in human plasma.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: